![Health / Organic chemistry / HIV/AIDS / Amides / Oxadiazoles / Raltegravir / Antiretroviral drug / ViiV Healthcare / GlaxoSmithKline / Organofluorides / Chemistry / Integrase inhibitors Health / Organic chemistry / HIV/AIDS / Amides / Oxadiazoles / Raltegravir / Antiretroviral drug / ViiV Healthcare / GlaxoSmithKline / Organofluorides / Chemistry / Integrase inhibitors](https://www.pdfsearch.io/img/a9af672b1fabab8ed0cdaa292eb562a0.jpg) Date: 2014-11-03 11:26:24Health Organic chemistry HIV/AIDS Amides Oxadiazoles Raltegravir Antiretroviral drug ViiV Healthcare GlaxoSmithKline Organofluorides Chemistry Integrase inhibitors | | Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatmAdd to Reading ListSource URL: shionogi616.tew-staging.comDownload Document from Source Website File Size: 106,12 KBShare Document on Facebook
|